{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:33:01Z","timestamp":1793730781997,"version":"4.6.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2010,6,8]]},"DOI":"10.1212\/wnl.0b013e3181e240d0","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T20:33:24Z","timestamp":1275942804000},"page":"1877-1885","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":52,"title":["Cross-sectional study assessing long-term safety of interferon-\u03b2-1b for relapsing-remitting MS"],"prefix":"10.1212","volume":"74","author":[{"given":"A.T.","family":"Reder","sequence":"first","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.C.","family":"Ebers","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Traboulsee","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Li","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Langdon","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Goodin","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bogumil","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Beckmann","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Konieczny","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (A.T.R.), University of Chicago, Chicago, IL; University Department of Clinical Neurology (G.C.E.), John Radcliffe Hospital, Oxford, UK; University of British Columbia (A.T., D.L.), Vancouver, British Columbia, Canada; Department of Psychology (D.L.), Royal Holloway, University of London, London, UK; Department of Neurology (D.S.G.), University of California, San Francisco; Bayer HealthCare Pharmaceuticals (T.B.), Montville, NJ; and Bayer Schering Pharma AG (K.B., A..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/112.1.133"},{"key":"e_1_3_3_3_2","first-page":"1416","volume":"56","year":"2001","unstructured":"Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001;56:1416.","journal-title":"Neurology"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1007oa"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(01)00637-2"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154522.86947.86"},{"key":"e_1_3_3_7_2","first-page":"3525","volume":"86","year":"2001","unstructured":"Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon-\u03b2-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86:3525\u20133532.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.655"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.7.1277"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.08.003"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.4.662"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1004oa"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"EuroQoL Group. EuroQoL: a new facility for the management of health-related quality of life. Health Policy 1990;16:199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.10.1941"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.9.1893"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000237641.33768.8d"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258545.73854.cf"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01386.x"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.0131"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.4.889"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.6.1277"},{"key":"e_1_3_3_22_2","first-page":"S54","volume":"7","year":"2001","unstructured":"Rice GP, Nicolle E, Lesaux J, Ebers GC, Kremenchutzky M, Karlik S. Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with interferon beta 1B. Mult Scler 2001;7(suppl 1):S54.","journal-title":"Mult Scler"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.58.4.417"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1990.00530010124031"},{"key":"e_1_3_3_25_2","unstructured":"Goodin D Jones J Ebers G et al. The interferon beta-1b 16-year long-term follow-up study: measuring efficacy after controlling for bias in long-term follow-up. Neurology 2009;72(11 suppl 3):P05.131 A237. Abstract."}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0b013e3181e240d0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T12:49:06Z","timestamp":1711630146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0b013e3181e240d0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2010,6,8]]}},"alternative-id":["10.1212\/WNL.0b013e3181e240d0"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0b013e3181e240d0","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}